AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05621941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-Supported Goal Management Training
Description: The investigational treatment is based on a compensatory strategy training named Goal Management Training (GMT). The investigational treatment will include GMT in combination with a compensatory strategy game which allows the patient to learn and apply the algorithm of GMT in a safe and controlled environment. This means that the multiple steps of the GMT will be learned during the treatment sessions under guidance of a therapist as well as in their own home environment by using the compensatory strategy game.
Study NCT05621941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Group
Description: In the information group, patients are informed about non-specific consequences of acquired brain injury, aimed to increase patient's insight into their condition and with that improving functioning. The program consists of the following subjects: 1) cause of brain injury, 2) information processing and attention, 3) memory, 4) planning and performance, 5) fatigue, 6) changes in emotion and behavior and 7) processing and adjustments.
Study NCT05165823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Description: Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
Study NCT04869722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid Model
Description: Whey protein beverages will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
Study NCT04869722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solid Model
Description: Protein fortified scones will be used, with the amount of fat varied to study the effect on perception of the products (using sensory methods rating mouthdrying and discrimination tests 'which sample is more mouthdrying') all measured at home.
Study NCT05138471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS intervention will consist in placing two electrodes, the cathode on the supraorbital surface on the same side as the painful knee, and the anode on the parietal area, corresponding to the area of the primary motor cortex, on the opposite side. The intensity will be 2 milli amperes (mA) and stimulation will be 20 minutes. The placebo will generate an initial sensation, and then descend until the stimulation is turned off.
Study NCT05138471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS intervention will consist in placing two electrodes on the sides of the patella of the affected knee. The frequency will be 10Herzts and the intensity will remain at a sensitive threshold level, without reaching the motor. The placebo will generate a sensation of current to descend to the minimum value that the equipment allows. Stimulation will last for 20 minutes.
Study NCT05723445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load Diet
Description: Food delivery service will provide a low glycemic load diet for 8 weeks, followed by a 4-month period of self-adherence to a low glycemic load diet with close nutritionist follow up
Study NCT06340256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous spinal anesthesia
Description: The Catheter will be then fed over the needle into the intrathecal space and Inserted 3cm cephalad into the subarachnoid space.The spinal needle and the modified Tuohy needle will be then removed, and a Luer connector and A filter previously filled with the anesthetic solution will be attached to the Catheter (priming volume 0.6ml). Plain bupivacaine 0.5% in 20ml vials will Be used CSA group received 1 ml(5 mg) of plain bupivacaine (0.5%) Together with fentanyl l25μg injected via the catheter at a rate of 0.2ml/15s. The level of the resulting sensory blockade will be tested using pin prick.
Study NCT05138471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and General Education
Description: The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
Study NCT05138471 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise and General Education
Description: The General Education Intervention consisting in an educational program will be applied to all groups using audiovisual material to increase the subject's knowledge about his/her pathology, about chronic pain and recommendations for supervised exercise based on the NEMEX protocol for osteoarthritis (Ageberg et al.)18: the participants will be taught analytical strengthening exercises (quadriceps and hamstrings) and neuromuscular functional exercises (getting up from the chair or going up a step), with their detailed dosage (2 to 3 series with 10 to 15 repetitions) and a home follow-up model where the participant must record compliance with exercise as well as pain during activity.
Study NCT05022511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening status
Description: Women are offered check-up on screening status in both CCU and CRC screening. If a woman is not up to date in one or both screening programmes, she will be offered a self-sampling device and/or a FIT kit.
Study NCT06340256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural anesthesia
Description: The needle is advanced until the epidural space is identified by the loss-of-resistance technique, and then a 20G catheter is inserted 3 cm cephalad into the epidural space. a test dose of 3ml of 2% lignocaine with adrenaline (1:200000) will be injected into the catheter. Three minutes later, 10 ml of plain bupivacaine (0.5%) together with fentanyl l50μg will be injected via the catheter.
Study NCT06363305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary capsules
Description: Daily doses of dietary capsaicin or placebo in capsule form
Study NCT06363305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary capsules
Description: Daily doses of dietary capsaicin or placebo in capsule form
Study NCT05918198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ven+CAG
Description: 100 mg on the first day, and then gradually increase to the target dose of 400 mg (100 mg d1, 200 mg d2, 400 mg d3) within 3 days; After that, the drug continued to be administered until the 14th day, 400 mg/day. When combined with CYP3A or P-gp inhibitors (mainly voriconazole in this study), adjust the venetoclax dose to 100 mg/day.~Ara-C 10mg/m2, ih, q12h × 14d； Acla 20mg/d × 4d； G-CSF 5ug/kg × 14d (WBC > 30 × 10\^9/L pause)
Study NCT05210595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Description: 75 mg/day as maintenance dose.
Study NCT05210595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60 twice daily after discharge or post PCI 1 week.
Study NCT05210595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 45 twice daily after discharge or post PCI 1 week .
Study NCT06156527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240mg, QD, daily
Study NCT06156527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib 240mg, QD, daily
Study NCT06156527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injectable Product
Description: Bevacizumab: 15mg/kg IV every 3 weeks
Study NCT05266404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/sitagliptin FDC
Description: Subjects will receive single dose of Dapagliflozin/sitagliptin FDC orally.
Study NCT05266404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will receive 100 mg single dose of Sitagliptin orally.
Study NCT05266404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Subjects will receive 10 mg single dose of Dapagliflozin orally.
Study NCT04624620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching Kitchen Collaborative Curriculum
Description: This is a referral-based teaching kitchen intervention that synergistically provides basic cooking skills, an evidence-based nutrition curriculum, mindfulness skills, activity tracking, and support for behavior change to augment weight management and lifestyle change in the primary care setting.
Study NCT05487547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL_RF_MGX
Description: intense pulsed light followed by Radiofrequency followed by meibomian gland expression
Study NCT05206344 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: clowns
Description: presence or absence of clowns during the performance of a painful act, on pain
Study NCT05136183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA-330 Disposable Hemoperfusion Cartridge (Jafron, China)
Description: * If no appropriate vascular access available, a double lumen catheter is placed by treating physicians, under ultrasonographic guidance.~* Two sessions of hemoperfusion using HA-330 Disposable Hemoperfusion Cartridge are performed 24 hours apart.~* Hemoperfusion is performed using either hemoperfusion or continuous renal replacement therapy machine. The optimal blood flow rate is 150-200 mL/min. The duration for each session in 2 hours. No systemic anticoagulant is given except for priming of the cartridge according to manufacturer recommendations.~* The first hemoperfusion session is recommended to be initiated within 12 hours after randomization.
Study NCT05391685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scar release techniques + therapeutic ultrasound
Description: Control group will be treated by therapeutic ultrasound only for2 sessions per week for two weeks Study group) will be treated by various scar release techniques in addition to therapeutic ultrasound, 2 sessions per week for two weeks.
Study NCT06162169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: JAB-21822 was administered orally
Study NCT06162169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole was administered orally
Study NCT06162169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole was administered orally
Study NCT06162169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam , Rosuvastatin calcium and digoxin
Description: Midazolam , Rosuvastatin calcium and digoxin was administered orally
Study NCT06162169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin was administered orally
Study NCT05986448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-chi exercise
Description: Traditional Chinese Tai Chi Movement
Study NCT05398718 — intervention group
Intervention type: DRUG
Intervention: Sotrovimab
Description: collect local clinical evidence for sotrovimab effect in the real-life setting
Study NCT05388318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged nightly fasting
Description: 14 hour nightly fast from caloric food and beverage; followed by 10 hour eating window. 8-week intervention duration.
Study NCT05388318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Weekly health education video viewing related to general health topics
Study NCT05979545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid Diagnostics
Description: Patients randomised to the intervention arm, will have the BioFire Blood Culture Identification 2 Panel (BCID2) used for positive blood cultures and/or the BioFire FilmArray Pneumonia plus PanelPneumonia Panel or Pneumonia plus Panel for respiratory tract specimens if having hospital-acquired pneumonia or ventilator-associated pneumonia. Standard of care diagnostics will also be used. Antibiotic guidelines will be provided to clinicians to aid interpretation of test results and treatment prescription. Ceftazidime-avibactam will be available for targeted use in patients with Pseudomonas aeruginosa or carbapenemase producing Enterobacterales.
Study NCT04803123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Patients must receive at least one dose of copanlisib prior to standard therapy to be evaluable.
Study NCT06105671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort
Description: Participants are administered 54 μg Formoterol and 1920 μg Budesonide
Study NCT06105671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Participants are administered 54 μg Formoterol from an inhaler device
Study NCT06105671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Participants are administered 120 μg Formoterol in a capsule, which is taken orally
Study NCT06105671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are administered placebo
Study NCT06105671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Participants are administered 600 mg Bronchitol
Study NCT04796402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Description: 700 mg/20mL IV over at least one hour OD
Study NCT04796402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care includes primary care and specialist care as indicated by the patient's primary care provider
Study NCT05200260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery
Description: Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
Study NCT05200260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: 3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
Study NCT05200260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARP inhibitor
Description: For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.
Study NCT05200260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor
Description: For patients with CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors. In this trial, Niraparib 200mg po qd is suggested after the front-line therapy.
Study NCT06013774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IXSI
Description: Hybrid imaging with IXSI will be performed during the radioembolization pre-treatment procedure
Study NCT05719922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training
Description: Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
Study NCT05070546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based Vaccine
Description: Participants will receive a single IM injection of an RSV vaccine.
Study NCT05070546 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of matching placebo.
Study NCT05719922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Comparing two different exercise-based treatment methodologies on the clinical outcomes of individuals with persistent knee pain.
Study NCT06064799 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA-223 & -214 detection
Description: miRNA-223 \& -214 detection in GCF samples by PCR kits
Study NCT04819633 — intervention group
Intervention type: OTHER
Intervention: Determination of serum sestrin levels
Description: Serum sestrin levels will be determined using venous blood samples obtained from the subjects.
Study NCT05854186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth solution: video conferencing
Description: Telehealth solution: video conferencing
Study NCT05689905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HLA typing of the children
Description: The HLA typing is made on a mouth swab of the children, that is a painless non-invasive procedure.
Study NCT05887999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered subcutaneously (SC).
Study NCT05887999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT05014854 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Usage of the SensoGrip-System comprised of the SensoGrip pen and a tablet app.
Description: Intervention consists of the usage of the SensoGrip-System in at least 6 and up to 8 therapy session together with the participating child. It is assumed that the standard frequency of therapy sessions is once a week, resuming in a span of 6-8 weeks. 10 minutes of every therapy session during the intervention phase must involve the application of the SensoGrip-System. Sample exercises are made available, therapists can freely choose which exercises are used.
Study NCT05788289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length.
Study NCT05788289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12).
Study NCT05857280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EXOPULSE Mollii Suit Stimulation
Description: We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms.
Study NCT05857280 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EXOPULSE Mollii Suit Stimulation
Description: We designed a randomized crossover, sham-controlled, double-blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of active versus sham EXOPULSE Mollii suit stimulation. in phase 1, the patient will receive two stimulations separated by a two-week washout period. The patients will be randomized to receive either active/sham or sham/active and both patients and investigators will be blinded to the order in which the stimulation will be given. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of phase 1, a second open label phase (phase 2) of this trial will be proposed to all patients where they will receive active stimulation every other day at home over four weeks (for a total of 14 sessions). This will help understand the long term effects of EXOPULSE Mollii suit stimulation on MS related symptoms.
Study NCT04993664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen (TQJ230)
Description: The first group will receive pelacarsen. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
Study NCT04993664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The second group will receive placebo. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
Study NCT04927208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and nutritional support
Description: resistance exercise and protein supplementation including branched chain amino acids for 12 weeks~Other: Combined exercise and nutrition intervention resistance exercise and nutritional supplementation for 12 weeks